Interventional × Myelodysplastic-Myeloproliferative Diseases × Mycophenolic Acid × Clear all
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT03246906 2025-06-04

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT00096161 2020-01-31

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 13 charts
NCT01527045 2020-01-02

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
47 enrolled 18 charts
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00044954 2019-09-17

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
NCT00290628 2017-11-29

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
43 enrolled
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00075478 2017-05-15

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 3 Completed
87 enrolled 16 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT00255684 2016-11-03

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

University of Rochester

Phase NA Terminated
16 enrolled 6 charts
NCT00295997 2014-01-06

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

National Cancer Institute (NCI)

Phase NA Unknown
35 enrolled
NCT00096096 2010-05-13

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Completed
NCT00006042 2010-03-10

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed